Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Radiation Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1395787

The role and value of radiotherapy in treatment of inflammatory myofibroblastic tumor

Provisionally accepted
Haiwei Guo Haiwei Guo 1,2*Mingyun Jiang Mingyun Jiang 3Mingyun Jiang Mingyun Jiang 4Ruiqi Liu Ruiqi Liu 3Weiping Yao Weiping Yao 3Xiaodong Liang Xiaodong Liang 3Haibo Zhang Haibo Zhang 3
  • 1 Zhejiang Provincial People's Hospital, Hangzhou, China
  • 2 Department of Head and Neck Surgery, Center of Otolaryngology-head and neck surgery, Zhejiang Provincial People's Hospital (People's Hospital of Hangzhou Medical College), Hangzhou, China
  • 3 Department of Radiation Oncology, Zhejiang Provincial People's Hospital, Hangzhou, Jiangsu Province, China
  • 4 Department of Pathology, Zhejiang Provincial People's Hospital, Hangzhou, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    Background: Inflammatory myofibroblastic tumors (IMTs) are rare soft-tissue neoplasms. Accordingly, there is no standardized therapy for unresectable or advanced IMT. Chemotherapy, radiotherapy, and targeted molecular therapy play an important role in unresectable or advanced IMT.We present a 54-year-old man with a cough and chest distress case report. The thoracic surgeon performed the right upper pulmonary occupying lesion wedge resection and enlarged lymph node excision biopsy. Pathologic diagnosis revealed that the morphology of "right upper lung mass" was considered as Inflammatory Myofibroblastic Tumor (IMT). Radiotherapy was indicated at a high dose: 5400cGy in 27 fractions of 2Gy over 5 weeks were delivered combined with cisplatin. The patient was given a CT/MRI and hematological index every 3 months and experienced no more adverse events. The patient survives with no tumor recurrence as of the last follow-up. Progression-free survival (PFS) exceeded 5 years.We have reviewed the literature and summarized and discussed the radiotherapy treatment options and challenges for IMT. We first reported high-dose radiotherapy combined with chemotherapy treatment for unresectable IMT. Concurrent radiochemotherapy may be considered an intensive treatment for local progress, local recurrence, and nonresectable IMT patients.

    Keywords: inflammatory myofibroblastic tumor, Radiotherapy, Radiation dose, Concurrent radiochemotherapy, case report

    Received: 15 Mar 2024; Accepted: 28 Oct 2024.

    Copyright: © 2024 Guo, Jiang, Jiang, Liu, Yao, Liang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Haiwei Guo, Zhejiang Provincial People's Hospital, Hangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.